PROKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
PROKIDNEY CORP.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$1.40+0.06 (+4.89%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Prokidney statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Prokidney | Industry median |
|---|---|---|
| Market Cap | $421.74M | $164.85M |
| Enterprise Value | $346.87M | $87.06M |
| PS Ratio | 515.58 | 3.60 |
Enterprise value
| Measure | Prokidney | Industry median |
|---|---|---|
| EV / Sales | 424.05 | 2.43 |
Income (trailing twelve months)
| Measure | Prokidney | Industry median |
|---|---|---|
| Revenue | $818.00K | $57.94M |
| Operating Income | -$177.22M | -$21.44M |
| Pretax Income | -$166.78M | -$14.45M |
| Net Income | -$84.16M | -$22.46M |
| EBITDA | -$170.37M | -$16.91M |
Margins
| Measure | Prokidney | Industry median |
|---|---|---|
| Operating Margin | -21664.5% | -44.5% |
| Pretax Margin | -20388.4% | -13.0% |
| Profit Margin | -10288.4% | -39.2% |
| EBITDA Margin | -20827.6% | -31.3% |
| FCF Margin | -19527.4% | -8.85% |
Returns
| Measure | Prokidney | Industry median |
|---|---|---|
| Return on Assets (ROA) | -27.1% | -41.0% |
| Return on Capital Employed (ROCE) | -78.3% | -37.8% |
Growth
| Measure | Prokidney | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 55.2% | 6.01% |
Balance sheet
| Measure | Prokidney | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $74.87M | $62.42M |
| Net Cash (Debt) | $74.87M | $15.68M |
| Net Cash Per Share | $0.25 | $0.66 |
| Equity (Book Value) | -$883.53M | $48.79M |
| Book Value Per Share | -$2.92 | $1.36 |
| Tangible Book Value | -$883.53M | $23.06M |
| Working Capital | $167.06M | $75.77M |
Financial position
| Measure | Prokidney | Industry median |
|---|---|---|
| Current Ratio | 8.36 | 3.30 |
| Quick Ratio | 3.30 | 2.39 |
| Interest Coverage | -9327.16 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Prokidney | Industry median |
|---|---|---|
| Operating Cash Flow | -$141.17M | -$12.35M |
| Capital Expenditures | -$18.57M | -$1.06M |
| Free Cash Flow | -$159.73M | -$20.28M |
| FCF Per Share | -$0.53 | -$0.42 |
Efficiency
| Measure | Prokidney | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.38 |
| Revenue Per Employee | $3.54K | $398.96K |
| Profits Per Employee | -$364.33K | -$703.34K |
| Employee Count | 231 | 74 |
Dividends and yields
| Measure | Prokidney | Industry median |
|---|---|---|
| Earnings Yield | -20.0% | -22.7% |
| FCF Yield | -37.9% | -9.07% |
| Buyback Yield | -5.75% | -0.73% |
| Shareholder Yield | -5.75% | 0.00% |
Shares
| Measure | Prokidney | Industry median |
|---|---|---|
| Shares Outstanding | 302,323,000 | 58,179,650 |
| Float | 113,026,000 | 49,173,100 |
| Shares Held by Insiders | 62.6% | 11.6% |
| Shares Held by Institutions | 15.8% | 59.4% |
Taxes
| Measure | Prokidney | Industry median |
|---|---|---|
| Income Tax | -$1.03M | $91.50K |
Scores
| Measure | Prokidney | Industry median |
|---|---|---|
| Altman Z-Score | 0.71 | -0.24 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Prokidney's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.